LTRN Q1 2023 Earnings — Lantern Pharma Inc. Revenue & Financial Results | Market Cap Arena

LTRNLantern Pharma Inc.

$31M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-0.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$333,530

Balance Sheet

Total Assets

$56M

Total Liabilities

$3M

Stockholders' Equity

$53M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$4M	-5.4%
Net Income	-$4M	-$4M	+6.2%